Christopher Michael Bull
Keine laufenden Positionen mehr
Profil
Christopher Michael Bull served as the Independent Non-Executive Chairman at African Dawn Capital Ltd.
from 2015 to 2015.
He also worked as a Director at Oxyrane UK Ltd.
Additionally, he pursued an undergraduate degree at the University of KwaZulu-Natal.
Ehemalige bekannte Positionen von Christopher Michael Bull
Unternehmen | Position | Ende |
---|---|---|
AFRICAN DAWN CAPITAL LIMITED | Vorsitzender | 12.06.2015 |
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ausbildung von Christopher Michael Bull
University of KwaZulu-Natal | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AFRICAN DAWN CAPITAL LIMITED | Finance |
Private Unternehmen | 1 |
---|---|
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Health Technology |